SummaryTafasitamab and lenalidomide were approved for second-line treatment of diffuse large B-cell lymphoma (DLBCL) based on a single-arm phase II study. This combination was superior to routine immunochemotherapy regimens when comparing matched observational cohorts. “Synthetic” control groups may support use of novel DLBCL therapies in the absence of randomized studies.See related article by Nowakowski et al., p. 4003

中文翻译：

---

拓宽思路：他法西他单抗和来那度胺与合成对照

摘要基于单组 II 期研究，Tafasitamab 和来那度胺被批准用于弥漫性大 B 细胞淋巴瘤 (DLBCL) 的二线治疗。在比较匹配的观察队列时，这种组合优于常规免疫化疗方案。在缺乏随机研究的情况下，“合成”对照组可能支持使用新型 DLBCL 疗法。请参阅 Nowakowski 等人的相关文章，第 17 页。4003